PROTACs: great opportunities for academia and industryXiuyun Sun, Yu Rao, Hongying Gao et al.|Signal Transduction and Targeted Therapy|2019Cited by 627
PROTAC Technology: Opportunities and ChallengesHongying Gao, Yu Rao, Xiuyun Sun|ACS Medicinal Chemistry Letters|2020Cited by 353
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignanciesYonghui Sun, Yu Rao, Yue Wu et al.|Cell Research|2018Cited by 280
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera DegradersShang Su, Yu Rao, Zimo Yang et al.|Journal of Medicinal Chemistry|2019Cited by 197
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapyYu Rao, Xuejing Shao, Tianbai Zhong et al.|Nature Chemical Biology|2021Cited by 162